Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 May;8(5):1086-1095.
doi: 10.1002/acn3.51353. Epub 2021 Mar 31.

Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy

Affiliations
Clinical Trial

Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy

Jacqueline Montes et al. Ann Clin Transl Neurol. 2021 May.

Abstract

Objective: To estimate muscle oxygen uptake and quantify fatigue during exercise in ambulatory individuals with spinal muscular atrophy (SMA) and healthy controls.

Methods: Peak aerobic capacity (VO2peak ) and workload (Wpeak ) were measured by cardiopulmonary exercise test (CPET) in 19 ambulatory SMA patients and 16 healthy controls. Submaximal exercise (SME) at 40% Wpeak was performed for 10 minutes. Change in vastus lateralis deoxygenated hemoglobin, measured by near-infrared spectroscopy, determined muscle oxygen uptake (ΔHHb) at rest and during CPET and SME. Dual energy X-ray absorptiometry assessed fat-free mass (FFM%). Fatigue was determined by percent change in workload or distance in the first compared to the last minute of SME (FatigueSME ) and six-minute walk test (Fatigue6MWT ), respectively.

Results: ΔHHb-PEAK, ΔHHb-SME, VO2peak , Wpeak , FFM%, and 6MWT distance were lower (P < 0.001), and Fatigue6MWT and FatigueSME were higher (P < 0.001) in SMA compared to controls. ΔHHb-PEAK correlated with FFM% (r = 0.50) and VO2peak (r = 0.41) only in controls. Only in SMA, Fatigue6MWT was inversely correlated with Wpeak (r = -0.69), and FatigueSME was inversely correlated with FFM% (r = -0.55) and VO2peak (r = -0.69).

Interpretation: This study provides further support for muscle mitochondrial dysfunction in SMA patients. During exercise, we observed diminished muscle oxygen uptake but no correlation with aerobic capacity or body composition. We also observed increased fatigue which correlated with decreased aerobic capacity, workload, and body composition. Understanding the mechanisms underlying diminished muscle oxygen uptake and increased fatigue during exercise in SMA may identify additional therapeutic targets that rescue symptomatic patients and mitigate their residual disease burden.

PubMed Disclaimer

Conflict of interest statement

JM: advisory boards for Biogen, Roche, and Scholar Rock; consultant for Biogen. UM: consultant for Genentech/Roche. AMG, MPM, DU, FMH, KC, KMC, JC, MH, AKR, CEG, and DCD have no commercial relationships that are relevant to this study.

Figures

Figure 1
Figure 1
Muscle oxygen uptake measured as the relative change in deoxygenated hemoglobin (ΔHHb) during a CPET from rest to cool down in SMA (n = 19) and control (n = 16) participants. CPET, cardiopulmonary exercise tolerance test; SMA, spinal muscular atrophy. Light‐weight lines indicate ΔHHb for individual participants; heavy‐weight lines represent the median for SMA (green) and controls (black). Start, start of incremental exercise.
Figure 2
Figure 2
Muscle oxygen uptake measured as the relative change in deoxygenated hemoglobin (ΔHHb) during 10 minutes of submaximal exercise (SME) from warm‐up to cool down in SMA (n = 19) and control (n = 16) participants. Light‐weight lines indicate ΔHHb for individual participants; heavy‐weight lines represent the median for SMA (green) and controls (black). M, minute; SMA, spinal muscular atrophy.
Figure 3
Figure 3
(A and B) Fatigue represented as percent change in (A) distance walked from 1st minute to the 6th minute of the 6MWT and (B) workload from the 1st minute to the 10th minute of submaximal cycle exercise in SMA participants (n = 19) and healthy controls (n = 16). 6MWT, six‐minute walk test; SME, submaximal exercise; SMA, spinal muscular atrophy. *P < 0.001.

References

    1. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q‐linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 2017;12:124. - PMC - PubMed
    1. Feldkötter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real‐time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358–368. - PMC - PubMed
    1. Rossoll W, Jablonka S, Andreassi C, et al. Smn, the spinal muscular atrophy‐determining gene product, modulates axon growth and localization of beta‐actin mRNA in growth cones of motoneurons. J Cell Biol 2003;163:801–812. - PMC - PubMed
    1. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. N Engl J Med 2018;378:625–635. - PubMed
    1. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019;29:842–856. - PMC - PubMed

Publication types

MeSH terms